Navigation Links
Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product
Date:12/5/2007

6% to 0.1%. Similarly, in a xenograft model of human liver cancer, anti-HAAH antibodies inhibited tumor growth in all animals, with 40% showing no visible tumor. In an animal model of metastatic human colon cancer, treatment with anti-HAAH antibodies inhibits metastasis. To date, PAN-622 has demonstrated the best performance in xenograft models of human liver cancer as measured by inhibition of tumor growth, and thus has been selected as Panacea's lead anti-cancer drug candidate. In recent experiments, nude mice were injected subcutaneously with a human liver cancer cell line and tumors were allowed to grow for 3 days prior to the initiation of treatment. Animals were treated three times per week with PAN-622 or a non-relevant human IgG for four weeks. Mice were observed for a three weeks after the cessation of treatment. PAN-622 inhibited tumor growth in all animals by about 90%, with 40% showing no visible tumor. Tumors did not re-grow in these animals in the period after treatment cessation.

"PAN-622 has demonstrated excellent inhibition of tumor growth in animal models of cancer, and as a cancer-specific therapeutic, should have a low toxicity and adverse effect profile," commented Hossein Ghanbari, Ph.D, Founder, Chairman, CEO and CSO at Panacea Pharmaceuticals. "We are confident that the performance of PAN-622 in animals will be replicated in humans, and quite excited about the potential for this product to effectively treat a broad range of cancers."

HAAH was discovered by researchers at Brown University and the Rhode Island Hospital. Panacea holds worldwide exclusive rights to develop and commercialize therapeutic and diagnostic products based on HAAH, and as such owns the rights to PAN-622. PAN-622 is manufactured in high yield under cGMP guidelines, and should enter Phase 1 clinical trials in early 2009 with an initial indication for the treatment of hepatocellular carcinoma.

About Panacea's Oncology Platform

In addition to the
'/>"/>

SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... The partners of Urgent Care of Westchester and ... Almendral as their chief provider for advanced beauty treatments. ... opened facility’s plan to offer all of Westchester County ... Almendral is a board certified physician who is trained ... techniques. Her areas of expertise include Botox, Dermal Fillers, ...
(Date:5/28/2015)... On Sunday, June 21, 2015, Colorado residents will ... honor the strength, passion and endurance of those facing ... of this sunrise-to-sunset event symbolizes the challenging journey of ... raise funds and awareness to advance the care, support ... are encouraged to create their own experience as they ...
(Date:5/28/2015)... Dr. Jenyons’ Medical Weight Loss & Rejuvenation ... looking to undergo its advanced Micro-Needling skin rejuvenating procedure. ... able to get a single Micro-Needling treatment with plasma, ... three-treatment package, which costs $1,800, the clinic will add ... Juanita Jenyons, M.D., says Dr. Jenyons’ Medical Weight Loss ...
(Date:5/28/2015)... 28, 2015 Medelis, Inc., a specialty ... the company in the role of president. , “ Bill ... the CRO industry,” said Larry Flanagan, Medelis’ CEO and co-founder. ... through our next phase of growth.” , Taaffe joined ... from nine employees to over 4,500 employees, achieving 12 consecutive ...
(Date:5/28/2015)... May 28, 2015 Altima Technologies, ... Device Library for documenting and diagramming data center ... for the following product lines: , Manufacturer ... 5500, Chatsworth Products N-Series TeraFrame Cabinet, Middle Atlantic ... Eclipse, Fore Systems ForeRunner, Marantz America MM Series, ...
Breaking Medicine News(10 mins):Health News:Bella Diosa Med Spa Welcomes Botox Specialist to Yonkers Community 2Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 2Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 3Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:NetZoom™ Visio® Stencil Library Updates for EMC, Cisco, and Chatsworth Products 2
... Loosening of Welfare Reform Rules Alter Longstanding System of ... Current versions of both the House and Senate health ... fail to prevent millions of illegal aliens from accessing ... Immigration Reform (FAIR). And in a radical change from ...
... protein implicated in rare form of bowel disorder, researchers ... with painful, chronic bowel conditions such as Crohn,s disease ... from new research. , Scientists say they,ve spotted a ... of colitis, and the finding might have implications for ...
... Inc. (Nasdaq: SGMO ) today reported third quarter 2009 ... ended September 30, 2009, Sangamo reported a consolidated net loss ... consolidated net loss of $6.3 million, or $0.15 per share, ... 2009, the company had cash, cash equivalents, marketable securities and ...
... ), the largest provider of deathcare products and services in North America, today reported results for ... end of this press release. The table below summarizes our key financial results: , , ... ... (In millions, except for September 30, ...
... drug makers, consumers, patients , WEDNESDAY, Nov. 4 (HealthDay ... designed to reduce preventable injuries and deaths caused by ... will focus on preventable injuries and deaths caused by ... attempts at self- harm," Dr. Janet Woodcock, director of ...
... Allergy and Infectious Diseases (NIAID), part of the National ... two programs that support research to better understand the ... including those that may be introduced into a community ... to the Cooperative Centers for Translational Research on Human ...
Cached Medicine News:Health News:Health Care Reform Legislation Becomes Vehicle for Reshaping Immigration Policy 2Health News:Health Care Reform Legislation Becomes Vehicle for Reshaping Immigration Policy 3Health News:Gene Discovery Gives Clues to Crohn's Disease, Colitis 2Health News:Gene Discovery Gives Clues to Crohn's Disease, Colitis 3Health News:Sangamo BioSciences Reports Third Quarter 2009 Financial Results 2Health News:Sangamo BioSciences Reports Third Quarter 2009 Financial Results 3Health News:Sangamo BioSciences Reports Third Quarter 2009 Financial Results 4Health News:Sangamo BioSciences Reports Third Quarter 2009 Financial Results 5Health News:Sangamo BioSciences Reports Third Quarter 2009 Financial Results 6Health News:Sangamo BioSciences Reports Third Quarter 2009 Financial Results 7Health News:Sangamo BioSciences Reports Third Quarter 2009 Financial Results 8Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 2Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 3Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 4Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 5Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 6Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 7Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 8Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 9Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 10Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 11Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 12Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 13Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 14Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 15Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 16Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 17Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 18Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 19Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 20Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 21Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 22Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 23Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 24Health News:Service Corporation International Announces Third Quarter 2009 Financial Results 25
(Date:5/28/2015)... May 28, 2015 Zimmer Holdings, Inc. (NYSE ... finalized agreements with buyers to divest in ... Knee System assets, Biomet Discovery® Elbow System assets and ... furtherance of Zimmer,s pending acquisition of Biomet, Inc. ("Biomet").  ... to work constructively with the Bureau of Competition Staff ...
(Date:5/28/2015)... ZURICH , May 28, 2015  Maetrics ( ... the life sciences sector, wrapped up a successful conference, ... the Medical Technology industry," today in Zurich ... ( http://www.maetrics.ch ) and its Switzerland ... regulation on the Medical Technology field to an exclusive ...
(Date:5/28/2015)... YORK , May 28, 2015 ... ( http://www.morcellatorlawsuit2015.com )  in hysterectomies and myomectomies (procedures to ... indicates that the FBI is investigating Johnson & ... largest manufacturer of the devices. According to the ... May 27 th , the FBI is trying ...
Breaking Medicine Technology:Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6Maetrics Hosts Innovative Medical Cluster Event in Switzerland 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 3
... July 25, 2011 A leading international scientist in ... ask their dentists about the potential for cross-contamination in ... that fasten patients, protective bibs in place. ... Dr. John Molinari, Director of Infection Control for ...
... Prasco Laboratories, the Authorized Generics company, announced today it has signed ... the terms of the agreement, Prasco will ... Generic version of Ponstel ® . Prasco ... Prasco label. "With the introduction of the authorized ...
Cached Medicine Technology:Question Your Dentist About Potential for Cross-Contamination, Leading Infection-Control Scientist Tells Fox News 2Prasco® Announces Authorized Generic Agreement with Shionogi Inc. 2
Indications For Usage: ,Pediatric (recommended tidal volume 70-250ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intend...
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to...
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
... helps provide protection to the exposed airway of ... lightweight making it ideal for active young children ... of heat and moisture recovery, it ensures patient ... and filters have ISO standard tapered ends to ...
Medicine Products: